In silico exploitation of molecular markers of cancer from wet lab in the mechanism-based screening of potential anticancer compounds

摘要: Past several decades of intense research to study the diverse nature cancer initiation and development with associated risk factors modulators (e.g. lifestyle, environmental, dietary, genetic race) has resulted in innumerable number molecular cellular markers specific various types cancers. Further, some prominent common pathways (such as cell cycle, proliferation, apoptosis, angiogenesis metastasis) involved different cancers pathwaysspecific which have led elucidation mechanism(s) target organs. With emergence these a quest discover novel anticancer drugs least side-effects further exploit screening numerous natural synthetic compounds from origins. In other words, very same also provided important clues on mechanism action chemopreventive therapeutic agents and/or drugs. Several Vincristine, Vinblastine, Paclitaxel, Doxorubicin, ET-743, Dolastatin 10 etc.) 3,5 been discovered for treatment targeting marker(s) particular pathway modulating expression genes known be development. problem drug-induced sideeffects seems inherent due complexity carcinogenesis process involving multiple biochemical pathways. such complex multi-faceted pathway(s) cancers, simultaneous interaction drug is almost unavoidable inter-related inter-dependent The marker quite possible either positively or negatively influence pathways; may remain neutral. At time, it impossible economically unsustainable unfeasible pharmaceutical company screen all affected by likely candidate vitro vivo experimental models. Furthermore, most anti-cancer developed e.g. apoptosis induction cells inhibition leaving sites targets normal cells. Due economical reasons, potential candidates cannot timely tested using wet lab experiments could subsequently responsible short- long-term side effects that patients. recent years, severe complications side-effects, withdraw market come into limelight especially newly anti-angiogenic 2 .